0.6224
+0.0024
+(0.39%)
As of 12:42:41 PM EDT. Market Open.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
124,961
124,961
152,069
156,234
111,014
Cost of Revenue
39,227
39,227
27,020
18,748
15,832
Gross Profit
85,734
85,734
125,049
137,486
95,182
Operating Expense
104,517
104,517
109,008
79,394
80,755
Operating Income
-18,783
-18,783
16,041
58,092
14,427
Net Non Operating Interest Income Expense
182
182
-10,895
-7,961
-10,220
Other Income Expense
-2,928
-2,928
-259,200
-18,965
-4,760
Pretax Income
-21,529
-21,529
-254,054
31,166
-553
Tax Provision
52
52
77,888
-78,459
728
Net Income Common Stockholders
-21,581
-21,581
-331,942
109,625
-1,281
Average Dilution Earnings
--
--
--
1,560
--
Diluted NI Available to Com Stockholders
-21,581
-21,581
-331,942
111,185
-1,281
Basic EPS
-0.23
-0.23
-4.67
2.33
-0.03
Diluted EPS
-0.23
-0.23
-4.67
2.03
-0.03
Basic Average Shares
95,271
95,271
71,031
47,004
43,169
Diluted Average Shares
95,271
95,271
71,031
54,669
43,169
Total Operating Income as Reported
-24,476
-24,476
-243,536
-39,405
9,424
Total Expenses
143,744
143,744
136,028
98,142
96,587
Net Income from Continuing & Discontinued Operation
-21,581
-21,581
-331,942
109,625
-1,281
Normalized Income
-17,083.5300
-17,083.5300
-126,876.1700
124,387.7300
2,371.1900
Interest Income
3,221
3,221
2,403
--
--
Interest Expense
2,600
2,600
2,925
7,725
10,205
Net Interest Income
182
182
-10,895
-7,961
-10,220
EBIT
-18,929
-18,929
-251,129
38,891
9,652
EBITDA
6,900
6,900
-222,900
72,287
38,729
Reconciled Cost of Revenue
39,042
39,042
26,318
17,960
14,869
Reconciled Depreciation
25,829
25,829
28,229
33,396
29,077
Net Income from Continuing Operation Net Minority Interest
-21,581
-21,581
-331,942
109,625
-1,281
Total Unusual Items Excluding Goodwill
-5,693
-5,693
-259,577
-18,687
-5,003
Total Unusual Items
-5,693
-5,693
-259,577
-18,687
-5,003
Normalized EBITDA
12,593
12,593
36,677
90,974
43,732
Tax Rate for Calcs
0.0002
0.0002
0.0002
0.0002
0.0003
Tax Effect of Unusual Items
-1,195.5300
-1,195.5300
-54,511.1700
-3,924.2700
-1,350.8100
12/31/2021 - 12/3/1997
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
IRWD Ironwood Pharmaceuticals, Inc.
0.6591
-30.29%
ETON Eton Pharmaceuticals, Inc.
12.95
+4.02%
AVDL Avadel Pharmaceuticals plc
7.64
-0.59%
AYTU Aytu BioPharma, Inc.
1.0200
+0.99%
CPIX Cumberland Pharmaceuticals Inc.
4.0300
-0.74%
EVOK Evoke Pharma, Inc.
2.2338
-0.28%
OPTN OptiNose, Inc.
9.11
+0.44%
SXTC China SXT Pharmaceuticals, Inc.
2.5300
+1.98%
DRRX DURECT Corporation
0.7488
-0.03%
RMTI Rockwell Medical, Inc.
1.0600
0.00%